BioForce Nanosciences Net debt/EBITDA
Qual é o Net debt/EBITDA de BioForce Nanosciences?
O Net debt/EBITDA de BioForce Nanosciences Holdings, Inc. é -13.80
Qual é a definição de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA de empresas na Setor Consumer Staples em OTC em comparação com BioForce Nanosciences
O que BioForce Nanosciences faz?
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. The company is based in Virginia Beach, Virginia.
Empresas com net debt/ebitda semelhantes a BioForce Nanosciences
- Isabella Bank tem Net debt/EBITDA de -13.86
- Sinosoft Technology tem Net debt/EBITDA de -13.85
- Capita Plc tem Net debt/EBITDA de -13.84
- EGL tem Net debt/EBITDA de -13.82
- Atlas Pearls Ltd tem Net debt/EBITDA de -13.82
- Excelsior Mining tem Net debt/EBITDA de -13.81
- BioForce Nanosciences tem Net debt/EBITDA de -13.80
- Greenbrook TMS tem Net debt/EBITDA de -13.79
- Neogenomics tem Net debt/EBITDA de -13.78
- Onto Innovation tem Net debt/EBITDA de -13.78
- CBTX Inc tem Net debt/EBITDA de -13.76
- Christopher & Banks tem Net debt/EBITDA de -13.75
- Patagonia Gold tem Net debt/EBITDA de -13.74